CARISMA Therapeutics Inc, a clinical stage biopharmaceutical company, announced on Tuesday that it has named Richard Morris as its new chief financial officer.
Morris has over 25 years of experience in building and growing biotech organisations. He has served as CFO at Passage Bio. He has also held the position of executive vice president and CFO for Context Therapeutics and CFO for Vitae Pharmaceuticals. He has held various senior financial roles at ViroPharma and has served at the healthcare assurance practice at KPMG.
Morris earned a Bachelor of Science in accounting at Saint Joseph's University in Philadelphia, PA and is a certified public accountant.
Nuevocor names new chief medical officer
ELIAS Animal Health names new chief revenue officer
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
HealthTrackRx names new chief medical officer
PureTech announces launch of Seaport Therapeutics with USD100m Series A financing
REVIAN names new vice president of Healthcare Sales
Orsini Specialty Pharmacy names new CFO and EVP of Trade Relations and Account Management
Ligand Pharmaceuticals launches Pelthos Therapeutics to drive ZELSUVMI commercialisation
Soligenix announces agreement on design for second Phase 3 trial for HyBryte with EMA
Ratio Therapeutics names new chief business officer and director
Trevi Therapeutics names new vice president of Clinical Development
NeoImmuneTech names new president and chief executive officer